SEC-sourced researchBeta
BIOA
BioAge Labs, Inc.
Company comparison ↗
Data passport
- CIK
- 0001709941
- Exchange
- Nasdaq
- Business activity
- Pharmaceutical Preparations · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Nov 16, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 0.0000 | Mar 24, 2026 |
| December 2025 | 8,995,000.0000 | Mar 24, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 8,995,000.0000 | -80,605,000.0000 | -81,627,000.0000 | 294,889,000.0000 | 22,838,000.0000 | Mar 24, 2026 |
| December 2024 | 0.0000 | -71,109,000.0000 | -51,522,000.0000 | 358,234,000.0000 | 35,107,000.0000 | Mar 24, 2026 |
Explainable fundamental score
Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.
48/100
Profitability0
Growth—
Balance sheet92
Cash generation0
Data coverage100
Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $9M | Jan 1, 2025 – Dec 31, 2025 | Mar 24, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $0 | Jan 1, 2024 – Dec 31, 2024 | Mar 24, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$80.61M | Jan 1, 2025 – Dec 31, 2025 | Mar 24, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$81.63M | Jan 1, 2025 – Dec 31, 2025 | Mar 24, 2026 | 10-K |
| Total assetsAssets | $294.89M | Dec 31, 2025 | Mar 24, 2026 | 10-K |
| Total liabilitiesLiabilities | $22.84M | Dec 31, 2025 | Mar 24, 2026 | 10-K |